A provider briefing on VCF Vaginal Contraceptive Film availability in 2026. Current supply status, patient access challenges, and clinical alternatives.
If your patients have been asking about difficulty finding VCF Vaginal Contraceptive Film, you're not alone. While VCF is an over-the-counter product that doesn't require a prescription, many providers recommend it as part of a contraceptive strategy — and patient access challenges are increasingly landing in your office.
This briefing covers the current state of VCF availability, the factors driving access issues, and what you can do to help your patients navigate the situation.
VCF (Vaginal Contraceptive Film) is a thin, dissolvable film containing 28% nonoxynol-9, a surfactant spermicide. Manufactured by Apothecus Pharmaceutical Corp, it has been available OTC in the United States for decades. It's one of the few non-hormonal, on-demand contraceptive options patients can purchase without a prescription.
VCF is inserted vaginally at least 15 minutes before intercourse. Each film provides up to 3 hours of contraceptive protection. With perfect use, spermicide effectiveness is approximately 82%; with typical use, approximately 72%. It's most effective when used in conjunction with barrier methods.
1990s-2000s: VCF establishes itself as a leading OTC spermicide product, widely available at major pharmacies and retailers.
2010s: Retail pharmacy consolidation and shelf-space optimization lead to reduced stocking of niche OTC products, including spermicide films. Many chain pharmacies begin carrying fewer spermicide options.
2020: FDA approves Phexxi (lactic acid/citric acid/potassium bitartrate), the first non-hormonal vaginal contraceptive gel to enter the market in decades, creating a new alternative to nonoxynol-9 products.
2023: FDA approves OTC Opill (norgestrel), expanding over-the-counter contraceptive options. Growing interest in non-hormonal alternatives drives increased attention to products like VCF.
2024-2026: Patient demand for non-hormonal contraceptives continues to rise. VCF availability becomes more inconsistent at retail locations, with significant variation by region and pharmacy chain.
VCF occupies a unique clinical niche. It's one of the few non-hormonal, non-prescription contraceptive options available, making it particularly relevant for patients who:
Because VCF is OTC, it doesn't typically appear in your prescribing workflow. However, patients increasingly seek provider guidance on non-hormonal options, and being aware of availability challenges allows you to counsel more effectively.
As an OTC product, VCF is generally not covered by insurance. However, under the ACA's contraceptive coverage mandate, some insurance plans will cover OTC contraceptives when a provider writes a prescription. Writing a prescription for VCF may help your patients access insurance coverage — a step worth considering, especially for patients with cost concerns.
VCF's availability challenges differ from typical drug shortages in several important ways:
This is not a manufacturing shortage. Apothecus continues to produce VCF. The issue is downstream: retail pharmacies and drugstores inconsistently stock the product. Large chains allocate limited shelf space to spermicide products, and individual store managers may not prioritize reordering.
Availability is highly location-dependent. Urban areas with more pharmacy options tend to have better access. Rural areas may have fewer stores that carry VCF at all. Online retailers remain a consistent source.
VCF sits in a product category (OTC spermicides) that receives minimal retail attention compared to condoms or hormonal contraceptives. This means even a modest increase in demand can create localized stockouts.
Relative to other contraceptive methods, VCF is among the most affordable. However, patients who use it as their primary method and use it frequently will see costs accumulate.
Several trends are worth monitoring:
VCF Vaginal Contraceptive Film remains a clinically relevant non-hormonal option for many patients. While it's not facing a formal shortage, real-world availability challenges mean providers should be prepared to help patients navigate access issues.
Consider writing prescriptions for VCF to help patients access insurance coverage under ACA, direct patients to the Medfinder provider portal to check local availability, and be ready to discuss alternatives like Phexxi, condoms, or the copper IUD when VCF cannot be found.
Share our patient-facing VCF shortage update with your patients, and see our provider's guide to helping patients find VCF for more actionable steps.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
